Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Investment analysts at started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTXGet Free Report) in a report released on Thursday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE BTX opened at $1.90 on Thursday. The firm’s 50-day moving average is $2.16 and its two-hundred day moving average is $1.88. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The stock has a market capitalization of $111.77 million, a P/E ratio of -0.84 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

See Also

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with's FREE daily email newsletter.